<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0000947871-25-000166</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED ADVISORS LLC -->
          <cik>0001055951</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Shares, par value CHF 0.08 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001771910</issuerCik>
        <issuerName>ADC Therapeutics SA</issuerName>
        <issuerCusip>H0036K147</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>Biopole</com:street1>
          <com:street2>Route de la Corniche 3B</com:street2>
          <com:city>Epalinges</com:city>
          <com:stateOrCountry>V8</com:stateOrCountry>
          <com:zipCode>1066</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>ORBIMED ADVISORS LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>2592057.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>2592057.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2592057.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>2.1</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>ORBIMED CAPITAL LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3230797.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3230797.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3230797.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>2.6</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ADC Therapeutics SA</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>Biopole Route de la Corniche 3B, 1066 Epalinges, Switzerland</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>OrbiMed Advisors LLC

OrbiMed Capital LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>601 Lexington Avenue, 54th Floor

New York, NY 10022</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Please refer to Item 4 on each cover sheet for each filing person.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>IA</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>OrbiMed Advisors LLC: 2,592,057

OrbiMed Capital LLC: 3,230,797</amountBeneficiallyOwned>
        <classPercent>OrbiMed Advisors LLC: 2.1%

OrbiMed Capital LLC: 2.6%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>OrbiMed Advisors LLC: 0

OrbiMed Capital LLC: 3,230,797</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>OrbiMed Advisors LLC: 2,592,057

OrbiMed Capital LLC: 0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>OrbiMed Advisors LLC: 0

OrbiMed Capital LLC: 3,230,797</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>OrbiMed Advisors LLC: 2,592,057

OrbiMed Capital LLC: 0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>The Reporting Persons hold 4.7% of the Common Shares in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the Common Shares through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Common Shares reported herein.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>ORBIMED ADVISORS LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Carl L. Gordon</signature>
        <title>Carl L. Gordon/Member</title>
        <date>02/17/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>ORBIMED CAPITAL LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Carl L. Gordon</signature>
        <title>Carl L. Gordon/Member</title>
        <date>02/17/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
